- Home
- BKE vs EWTX Comparison
BKE vs EWTX Comparison
Compare BKE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | EWTX |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.3B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BKE | EWTX |
|---|---|---|
| Price | $54.87 | $36.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $53.00 | $39.00 |
| AVG Volume (30 Days) | 316.2K | ★ 1.0M |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | ★ 6.43 | N/A |
| EPS | ★ 4.14 | N/A |
| Revenue | ★ $1,297,835,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.99 | N/A |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | ★ 6.58 | N/A |
| 52 Week Low | $36.48 | $12.31 |
| 52 Week High | $61.69 | $39.96 |
Technical Indicators
Market Signals| Indicator | BKE | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 66.22 |
| Support Level | $52.81 | $27.81 |
| Resistance Level | $56.58 | N/A |
| Average True Range (ATR) | 1.42 | 1.59 |
| MACD | -0.31 | 0.41 |
| Stochastic Oscillator | 45.69 | 70.63 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.